SCHEMBL26043564

SCHEMBL26043564

CS(=O)(=O)Nc1cccc(NC(=O)c2ccc(N3CCCC3)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.59
NR1H4 Q96RI1 3/20 0.59
DHX9 Q08211 1/20 0.59
HPGD P15428 1/20 0.58
RAB9A P51151 10/20 0.57
NPC1 O15118 9/20 0.57
MAPT P10636 8/20 0.57
SMN1; SMN2 Q16637 8/20 0.57
KMT2A Q03164 6/20 0.57
MEN1 O00255 4/20 0.57
MCL1 Q07820 3/20 0.57
KDM4E B2RXH2 2/20 0.57
LMNA P02545 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
TP53 P04637 3/20 0.55
PKM P14618 2/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
USP2 O75604 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26043484 0.82 HPGD (0.61) DHX9HPGDRAB9ANPC1MAPT
SCHEMBL31610145 0.80 KCNK3 (0.72) DHX9HPGDSMN1; SMN2KMT2AMEN1
SCHEMBL27681315 0.80 KCNK3 (0.72) DHX9HPGDSMN1; SMN2KMT2AMEN1
SCHEMBL31610077 0.80 MAPT (0.65) HPGDRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2347217 0.79 MAPK14 (0.61) RAB9ANPC1TP53PKMMAPK1
SCHEMBL4256420 0.79 RAB9A (0.78) RAB9ANPC1MAPTSMN1; SMN2KMT2A
SCHEMBL26043351 0.79 GAA (0.55) DHX9HPGDRAB9ANPC1MAPT
SCHEMBL4251987 0.79 RAB9A (0.85) HPGDRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL25368211 0.78 HPGD (0.65) DHX9HPGDSMN1; SMN2KMT2AMEN1
SCHEMBL30543903 0.78 HPGD (0.65) DHX9HPGDSMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B EPHX2 628/4885NR1H4 2542/4885DHX9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.